Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 30% Improvement Relative Risk Death/ICU 38% ICU admission 54% Oxygen therapy, day 30 42% Oxygen therapy, day 15 23% Recovery, day 30 29% Recovery, day 15 14% Hospitalization, outpatients 69% Hospitalization time, inp.. 33% Recovery time, outpatients 25% c19early.org/z Abdallah et al. NCT05212480 Zinc RCT EARLY TREATMENT Favors zinc Favors control
Twice daily oral zinc in the treatment of patients with Coronavirus Disease-19: A randomized double-blind controlled trial
Abdallah et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac807, NCT05212480 (history)
4 Nov 2022    Source   PDF   Share   Tweet
RCT 470 patients with symptoms ≤7 days, showing significantly lower ICU admission and combined mortality/ICU admission with zinc treatment. Greater benefit was seen for patients treated within 3 days. 25mg elemental zinc bid for 15 days.
risk of death, 29.9% lower, RR 0.70, p = 0.27, treatment 15 of 231 (6.5%), control 22 of 239 (9.2%), NNT 37, odds ratio converted to relative risk, day 30.
risk of death/ICU, 37.6% lower, RR 0.62, p = 0.04, treatment 24 of 231 (10.4%), control 40 of 239 (16.7%), NNT 16, odds ratio converted to relative risk, day 30.
risk of ICU admission, 54.0% lower, RR 0.46, p = 0.01, treatment 12 of 231 (5.2%), control 27 of 239 (11.3%), NNT 16, odds ratio converted to relative risk, day 30.
risk of oxygen therapy, 41.7% lower, RR 0.58, p = 0.009, treatment 31 of 231 (13.4%), control 55 of 239 (23.0%), NNT 10, grade III, day 30, Figure 3.
risk of oxygen therapy, 22.9% lower, RR 0.77, p = 0.003, treatment 108 of 231 (46.8%), control 145 of 239 (60.7%), NNT 7.2, grade III, day 15, Figure 3.
risk of no recovery, 29.3% lower, RR 0.71, p = 0.002, treatment 82 of 231 (35.5%), control 120 of 239 (50.2%), NNT 6.8, grade II/III, day 30.
risk of no recovery, 13.8% lower, RR 0.86, p < 0.001, treatment 180 of 231 (77.9%), control 216 of 239 (90.4%), NNT 8.0, grade II/III, day 15.
risk of hospitalization, 69.1% lower, RR 0.31, p = 0.30, treatment 1 of 85 (1.2%), control 4 of 100 (4.0%), NNT 35, odds ratio converted to relative risk, outpatients.
hospitalization time, 33.0% lower, relative time 0.67, p < 0.001, treatment mean 7.1 (±3.4) n=146, control mean 10.6 (±2.8) n=134, inpatients.
recovery time, 25.0% lower, relative time 0.75, p < 0.001, treatment mean 9.6 (±4.1) n=85, control mean 12.8 (±6.7) n=100, outpatients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abdallah et al., 4 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Tunisia, peer-reviewed, mean age 54.2, 24 authors, study period 15 February, 2022 - 4 May, 2022, average treatment delay 4.6 days, trial NCT05212480 (history).
Contact: semir.nouira@rns.tn, belhajalikhaoula@yahoo.fr.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit